Company / Capital Expenditures
Ligand Pharmaceuticals, Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$452.0K
FY2025
5-year range
$452.0K / $17.9M
FY2021-FY2025
Trend
-75.2%
vs FY2024
Sector context
#141 of 194
Health Care
What the data says
At $452,000, Ligand Pharmaceuticals, Inc.'s capital expenditures ranks #141 of 194 in the Health Care sector. Capital Expenditures has declined for 3 consecutive years, from $18M in FY2022 to $452,000 in FY2025.
Based on SEC 10-K filings.
$452,000 in FY2025 with a 5-year CAGR of -36.7%.
Declined from $4M to $452,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -70.7%
- 5-Year CAGR
- -36.7%
- 10-Year CAGR
- -
Sector benchmark
#141 of 194 in Health CareTop 73% of 194This company $452.0K Sector average $117.5M
▼
-99.6% below sector average
Key checks
Key Insights
- Ligand Pharmaceuticals, Inc.'s capital expenditures has declined for 3 consecutive years.
- 5-year CAGR of -36.7%, indicating a declining trend.
- In FY2025, capital expenditures decreased 75.2% year-over-year.
- Ranks #141 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $452.0K | -75.2% |
| FY2024 | $1.8M | -48.3% |
| FY2023 | $3.5M | -80.4% |
| FY2022 | $17.9M | +104.6% |
| FY2021 | $8.8M | +96.5% |
| FY2020 | $4.5M | +74.6% |
| FY2019 | $2.6M | +187.8% |
| FY2018 | $887.0K | -58.9% |
| FY2017 | $2.2M | +16.5% |
| FY2016 | $1.9M | +1889.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026